<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This report, the fifth of a series, summarizes indications and donor source of hematopoietic precursor cell transplants performed in Europe in 1994 and illustrates the evolution since 1990 </plain></SENT>
<SENT sid="1" pm="."><plain>306 teams in 30 participating countries performed a total of 10 066 transplants, 3502 allogeneic and 6564 autologous transplants </plain></SENT>
<SENT sid="2" pm="."><plain>In 1990, there were only 143 teams and a total of 4234 transplants, 2137 allogeneic and 2097 autologous transplants </plain></SENT>
<SENT sid="3" pm="."><plain>Main indications in 1994 were <z:hpo ids='HP_0001909'>leukemias</z:hpo> with 3881 transplants (39%), 2635 allogeneic (75%) and 1246 autologous (19%) transplants; <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with 3760 transplants (37%), 245 allogeneic (7%) and 3515 autologous (54%) transplants; severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with 250 transplants (2%), 248 allogeneic (7%) and 2 autologous transplants; <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> with 1800 transplants (18%), 13 allogeneic and 1787 autologous (27%) transplants and <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorders</z:e> with 375 (4%) transplants, 361 allogeneic (11%) and 14 autologous transplants </plain></SENT>
<SENT sid="4" pm="."><plain>The relative proportion of the main indication has stayed unchanged for allogeneic transplants </plain></SENT>
<SENT sid="5" pm="."><plain>There was, in contrast, a marked increase in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, ie mainly for <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo>, as an indication for autologous transplants since 1990 </plain></SENT>
<SENT sid="6" pm="."><plain>For the 3502 allogeneic transplants, the donor was an HLA-identical sibling in 2677 cases (76%), an HLA non-identical family member in 195 cases (6%), a syngeneic twin in 45 cases (1%) and an unrelated donor in 585 cases (17%) </plain></SENT>
<SENT sid="7" pm="."><plain>Donor source was bone marrow for 3322 allogeneic (95%) and 1869 autologous (29%) transplants, peripheral blood for 180 allogeneic (5%) and 4289 autologous (65%) transplants and a combination of bone marrow and peripheral blood for a few allogeneic and 406 autologous (6%) transplants </plain></SENT>
<SENT sid="8" pm="."><plain>The relative proportion of peripheral blood as a source for autologous transplants has changed since 1991 from 15 to 72.1% in 1994 </plain></SENT>
<SENT sid="9" pm="."><plain>A similar trend for allogeneic transplants is just emerging </plain></SENT>
</text></document>